Co-Diagnostics
CODX
45 hedge funds and large institutions have $16.3M invested in Co-Diagnostics in 2020 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,869% more capital invested
Capital invested by funds: $827K → $16.3M (+$15.5M)
1,233% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 3
350% more funds holding
Funds holding: 10 → 45 (+35)
205% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $1.78M
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.1% more ownership
Funds ownership: 0.18% → 0.28% (+0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 3 |
Millennium Management
New York
|
+$600K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$586K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$422K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$573K |
| 2 |
Barclays
London,
United Kingdom
|
-$78K |
| 3 |
Renaissance Technologies
New York
|
-$14K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4K |
CODX Hedge Fund Activity: Q1 2020 in Review
45 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2020, worth a combined $16.3M — up 1,869% from $827K a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CODX positions and 3 closed out — a net gain of 37 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $2.13M. The largest seller was HighTower Advisors, cutting an estimated $573K.
- 45 institutional investors held Co-Diagnostics (CODX) as of Q1 2020, up from 10 in Q4 2019.
- Funds reported $16.3M of Co-Diagnostics stock for Q1 2020, up 1,869% quarter-over-quarter.
- 40 funds opened new Co-Diagnostics positions in Q1 2020 and 3 closed out, a net change of +37 holders.
- The largest Co-Diagnostics buyer in Q1 2020 was Morgan Stanley, an estimated $2.13M added.
- The largest Co-Diagnostics seller in Q1 2020 was HighTower Advisors, an estimated $573K sold.
Based on aggregated 13F filings for Q1 2020.